Promising stomach cancer combo trial pulled before it even started

NCT ID NCT06967987

Terminated Disease control Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if adding a targeted drug (bemarituzumab) to standard chemotherapy (FLOT) could improve outcomes for people with a certain type of stomach or gastroesophageal junction cancer that overexpresses FGFR2b. The treatment was given before and after surgery. However, the trial was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC AND GASTRO-OESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMAS OVEREXPRESSION FGFR2B

Contacts and locations

Locations

CHRU de Brest

Brest, 29609, France
CHU de Poitiers

Poitiers, 86021, France
CHU de Rennes

Rennes, 35000, France
Centre François Baclesse

Caen, 14076, France
Centre Georges François Leclerc

Dijon, 21079, France
Centre Léon Bérard

Lyon, 69373, France
Gustave Roussy

Villejuif, 94805, France
Institut Bergonié

Bordeaux, 33000, France
Institut Paoli Calmette

Marseille, 13273, France
Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, 54519, France
Institut de Cancérologie de l'Ouest

Angers, 49055, France
Institut de Cancérologie de l'Ouest

Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.